The most common examples of genetic testing in fertility care include carrier screening, single-gene tests, expanded panels (CFTR, FMR1), preimplantation genetic testing for aneuploidy (PGT-A), PGT for monogenic conditions (PGT-M), PGT for structural rearrangements (PGT-SR), karyotype analysis, chromosomal microarray (CMA), mitochondrial testing, and, in select complex cases, whole-exome or whole-genome sequencing (WES/WGS).
At a glance, the tests you are most likely to encounter:
- Carrier screening / expanded carrier panels (preconception or early IVF workup)
- Single-gene and targeted single-variant tests (when a known familial variant exists)
- FMR1 testing (fragile X premutation, especially for women with diminished ovarian reserve)
- CFTR testing (cystic fibrosis carrier status)
- PGT-A (embryo aneuploidy screening during IVF)
- PGT-M (embryo testing for a specific inherited condition)
- PGT-SR (embryo testing for chromosomal structural rearrangements)
- Karyotype (chromosomal structure in blood sample)
- Chromosomal microarray (CMA) (higher-resolution chromosomal analysis)
- Mitochondrial testing (in specific clinical contexts)
- WES/WGS (reserved for complex, unresolved diagnostic questions)
Clinical-grade, provider-ordered tests are required for reproductive medical decisions; for a technical primer on these test categories and clinical use, see Understanding the main types of genetic tests for health. Direct-to-consumer (DTC) kits are not a substitute. Always review results with a genetic counselor before acting on them.
Table of Contents
- Common genetic tests in fertility and what each one checks for
- How and when each test is performed
- Clinical-grade testing vs. DTC tests: why the difference matters for fertility
- Interpreting results and deciding what to do next
- Costs, turnaround time, and insurance coverage in the U.S.
- When WES/WGS is considered and the limits of genetic testing
- How to choose the right tests and what to ask your clinic
- Key Takeaways
- Why genetics belong at the center of individualized IVF planning
- Lifeivfcenter’s integrated genetic testing and IVF support
- Authoritative U.S. resources for further reading
Common genetic tests in fertility and what each one checks for
MedlinePlus categorizes genetic tests into molecular, chromosomal, and biochemical types, with the choice depending entirely on the clinical question. In fertility care, the following tests carry the most direct implications for treatment planning.
Carrier screening (expanded carrier panels) checks whether one or both partners carry a recessive variant for conditions such as cystic fibrosis, spinal muscular atrophy, or Tay-Sachs. NCBI’s Understanding Genetics describes carrier testing as a standard tool in preconception and infertility evaluation. When both partners carry the same recessive variant, there is a significant risk of an affected child per pregnancy, which directly shapes decisions about IVF with PGT-M or donor gametes.
Single-gene and targeted single-variant tests are ordered when a specific pathogenic variant is already known in the family. Rather than scanning a broad panel, the lab confirms whether that exact variant is present. This is often the first step before building a PGT-M assay for embryo testing.
FMR1 testing screens for a fragile X premutation. Women who carry an FMR1 premutation have a higher rate of primary ovarian insufficiency and diminished ovarian reserve, making this test particularly relevant for women with unexplained low ovarian reserve or a family history of fragile X syndrome.
CFTR testing identifies cystic fibrosis carrier status. Men with congenital bilateral absence of the vas deferens (CBAVD) almost always carry CFTR variants, so CFTR testing is a standard part of male-factor infertility evaluation.
PGT-A screens embryos for the correct number of chromosomes (euploidy) before transfer. Aneuploid embryos, those with too many or too few chromosomes, are the leading cause of failed implantation and early miscarriage. PGT-A is most commonly offered to patients over 35, those with recurrent pregnancy loss, or those with prior failed IVF cycles.
PGT-M tests embryos for a specific single-gene condition when both parents are confirmed carriers or one parent has a dominant condition. The lab first validates an assay using parental DNA, then applies it to each biopsied embryo to identify which are unaffected and suitable for transfer.
PGT-SR is used when one partner carries a chromosomal structural rearrangement, such as a balanced translocation. These rearrangements often produce unbalanced embryos that fail to implant or result in miscarriage, and PGT-SR identifies which embryos have a balanced or normal chromosomal complement.
Karyotype analysis examines the overall structure and number of chromosomes from a blood sample. It is typically ordered during an infertility workup when recurrent pregnancy loss or severe male-factor infertility is present.
Chromosomal microarray (CMA) offers higher resolution than a standard karyotype, detecting smaller deletions and duplications that a karyotype would miss. CMA is used both in infertility evaluation and as a diagnostic tool after a pregnancy loss.
Mitochondrial testing is ordered in specific clinical contexts, such as suspected mitochondrial disease in a prior child or maternal-line family history. It is not a routine part of standard IVF workups.
Pro Tip: Before any test is ordered, ask whether the laboratory is CLIA-certified and CAP-accredited. CLIA/CAP accreditation is the baseline quality signal for clinical reproductive genetic testing in the U.S.
How and when each test is performed
Timing varies by test type. Carrier screening and karyotype analysis are typically completed before an IVF cycle begins. PGT requires an active IVF cycle because it involves biopsying embryos at the blastocyst stage (day 5–6). Prenatal diagnostic testing, such as amniocentesis or chorionic villus sampling, occurs after conception when indicated by prior carrier results or abnormal prenatal screening.
Typical touchpoints in an IVF cycle with genetic testing:
- Pre-IVF consultation: Review family history, order carrier screening and karyotype if indicated, refer to genetic counselor.
- Sample collection (blood or saliva): Both partners provide samples; results return in 1–3 weeks for most panels.
- IVF stimulation and egg retrieval: Eggs are fertilized and embryos are cultured to the blastocyst stage.
- Embryo biopsy: A few cells are removed from each blastocyst and sent to the PGT lab; embryos are vitrified (frozen) while awaiting results.
- Lab analysis and reporting: PGT results typically return within 7–14 days.
- Result counseling and transfer planning: A genetic counselor or reproductive endocrinologist reviews findings with the patient before a transfer decision is made.
| Sample type | Typical test(s) | Who collects it |
|---|---|---|
| Blood draw | Karyotype, carrier panel, single-gene test | Phlebotomist at clinic or lab |
| Saliva / buccal swab | Carrier panel, FMR1, CFTR | Patient (at-home kit or clinic) |
| Embryo biopsy | PGT-A, PGT-M, PGT-SR | Embryologist in IVF lab |
| Polar body | PGT (alternative to blastocyst biopsy) | Embryologist in IVF lab |
Clinical-grade testing vs. DTC tests: why the difference matters for fertility
CDC guidance is direct: clinical genetic tests are provider-ordered, often CLIA-regulated, and intended for specific medical decisions. DTC tests are consumer-ordered and should not be used alone to guide medical care.
The technical gap is significant. Clinical-grade tests use full DNA sequencing or validated targeted assays that detect a wide range of pathogenic variants, including rare ones. DTC kits typically use SNP genotyping arrays, which check only a limited set of known variants. FORCE explains that a DTC test can return a “negative” result while missing a pathogenic variant the clinical test would have found, because the array simply does not interrogate that position in the genome.
DTC ancestry and trait kits are not designed to detect the full spectrum of variants relevant to reproductive decisions. A negative DTC result does not rule out carrier status for conditions such as cystic fibrosis, spinal muscular atrophy, or BRCA-related hereditary cancer risk.
When a DTC result does flag a possible variant, such as a known Ashkenazi Jewish founder variant, confirmatory clinical sequencing and genetic counseling are the appropriate next steps before any reproductive decision is made.
Statistic to keep in mind: More than 77,000 genetic tests are currently in use across clinical and consumer settings. Matching the right test to the right clinical question requires provider guidance, not a consumer catalog.
Interpreting results and deciding what to do next
Results from genetic tests rarely point to a single automatic outcome. They open a conversation about options, and that conversation should always involve a genetic counselor.
Carrier results are the most common finding from preconception panels. Carrying one variant in a recessive gene is not a health risk for the carrier, but if both partners carry a variant in the same gene, each pregnancy has a 25% chance of being affected. Options at that point include proceeding with IVF and PGT-M, using donor gametes, or pursuing prenatal diagnostic testing in a natural conception.
PGT-A findings classify each embryo as euploid (normal chromosome count), aneuploid, or mosaic (a mix of normal and abnormal cells). Euploid embryos are prioritized for transfer. Mosaic embryos require careful counseling before a transfer decision, as outcomes vary.
PGT-M results identify which embryos are unaffected, carriers, or affected for the specific condition tested. Only unaffected or carrier embryos are typically considered for transfer, depending on the condition and the family’s preferences.
Variants of uncertain significance (VUS) are a common finding in large panels and WES/WGS. A VUS means the lab has identified a change in the DNA but cannot yet confirm whether it causes disease. NCBI guidance notes that reproductive teams treat VUS conservatively, relying on family testing and specialist review rather than using a VUS alone to exclude embryos.
A practical decision flow:
- Positive carrier result → test partner → if both carriers, consult genetic counselor about IVF + PGT-M, donor gametes, or prenatal testing
- Aneuploid embryo on PGT-A → counseling on transfer options (mosaic vs. aneuploid), consider additional embryo cycles if no euploid embryos remain
- VUS identified → request family testing, schedule specialist review, do not act on VUS alone
Pro Tip: If a DTC test flagged a variant, bring the full PDF report to your clinical appointment. Ask the provider to order confirmatory clinical sequencing before any reproductive decision is made.
Costs, turnaround time, and insurance coverage in the U.S.
Turnaround times follow a fairly consistent pattern: carrier panels and single-gene tests typically return results within 1–3 weeks; PGT results generally come back within 7–14 days after the embryo biopsy, though some labs offer expedited processing.
Costs vary by test scope and lab. Expanded carrier panels may range from a few hundred dollars to over $1,000 depending on the number of genes screened and whether insurance applies. PGT-A adds a per-embryo fee on top of the biopsy charge, and PGT-M typically costs more than PGT-A because of the custom assay development required for each couple. Confirmatory testing and genetic counseling visits carry their own fees.
Insurance coverage is inconsistent. Some plans cover carrier screening under preventive care, particularly when ordered preconception. PGT is less reliably covered and often requires a prior authorization with medical necessity documentation. Patients pursuing insurance coverage for fertility treatment should request itemized quotes from both the clinic and the reference lab before the cycle begins, and ask specifically whether the biopsy fee and the lab analysis fee are billed separately.
Clinics with package-based pricing can sometimes bundle genetic testing fees into a broader IVF package, which simplifies budgeting. Asking about package options at your initial consultation is worth the conversation.
When WES/WGS is considered and the limits of genetic testing
Whole-exome sequencing (WES) and whole-genome sequencing (WGS) are not routine tools in standard IVF care. MedlinePlus describes them as appropriate for complex or unresolved diagnostic cases, not first-line reproductive testing. In fertility settings, WES or WGS may be considered when a prior pregnancy had multiple congenital anomalies without a clear diagnosis, when a suspected genetic condition has not been identified by standard panels, or when complex unexplained infertility warrants a broader search.
Genetic testing of any kind has real limits. Not all genetic causes of infertility or pregnancy loss are currently understood. Many results are probabilistic rather than deterministic. And some findings, particularly secondary findings unrelated to the original clinical question, raise ethical questions about what families want to know before they are tested. Pre-test counseling about secondary findings is a standard part of responsible WES/WGS practice.
How to choose the right tests and what to ask your clinic
The fertility evaluation process is the natural starting point for this conversation. Come prepared.
Step-by-step preparation for a genetics visit:
- Compile a three-generation family history covering both partners, noting any genetic conditions, recurrent pregnancy losses, or unexplained infertility.
- Gather any prior genetic test reports, including DTC results, and bring the full PDF, not just a summary.
- Ask your provider whether the lab is CLIA-certified and CAP-accredited.
- Ask who will interpret your results: a board-certified genetic counselor or a reproductive endocrinologist with genetics training.
- Confirm whether PGT is performed in-house or sent to a reference lab, and ask for the lab’s name so you can verify accreditation independently.
- Request itemized pricing for each test, including biopsy fees, lab analysis, and counseling visits.
Red flags to watch for:
- A lab or clinic that will not provide a full written report with variant classifications
- Vague statements about detection rates without citing the specific panel or methodology
- Pressure to use a specific vendor without disclosing alternatives or conflicts of interest
- Results delivered without an offer of genetic counseling follow-up
Understanding the role of genetics in IVF before your first consultation puts you in a much stronger position to ask the right questions and evaluate the answers you receive.
Key Takeaways
Clinical-grade, provider-ordered genetic tests are the only appropriate basis for reproductive medical decisions, and each test type serves a distinct clinical purpose in the fertility and IVF process.
| Point | Details |
|---|---|
| Use clinical-grade tests only | Provider-ordered, CLIA/CAP-certified tests are required for IVF and embryo selection decisions. |
| Match the test to the question | Carrier panels for preconception risk; PGT-A/M/SR for embryo evaluation; WES/WGS only for complex unresolved cases. |
| VUS requires caution | Variants of uncertain significance should not be used alone to exclude embryos; specialist review is needed. |
| Confirm DTC results clinically | A negative DTC result does not rule out carrier status; always confirm with clinical sequencing before acting. |
| Lifeivfcenter integrates genetics into Precision IVF® | Lifeivfcenter’s Precision IVF® approach incorporates genetic testing into individualized treatment planning from the first consultation. |
Why genetics belong at the center of individualized IVF planning
Most fertility articles treat genetic testing as an optional add-on, something patients can pursue if they want extra reassurance. That framing misses the point. At Lifeivfcenter, genetics are built into Precision IVF® from the start, not offered as an afterthought.
The reason is straightforward: embryo selection without chromosomal data is guesswork dressed as medicine. When a patient’s treatment protocol is built around their actual biological profile, including carrier status, ovarian reserve markers, and embryo ploidy, the path to a successful transfer becomes clearer and shorter. Patients who have navigated recurrent loss or multiple failed cycles often describe the shift from “we’ll try and see” to “we know what we’re working with” as the most meaningful change in their care experience.
The genetic counseling conversation is where that shift begins. Lifeivfcenter’s clinical team recommends scheduling a genetics consultation before the first IVF cycle, not after a failed one. Knowing the genetic landscape in advance shapes every subsequent decision, from protocol design to embryo transfer timing to donor screening criteria.
Lifeivfcenter’s integrated genetic testing and IVF support
Lifeivfcenter offers something most patients don’t realize they need until they’re mid-cycle: a fully integrated genetic testing pathway built into the IVF process from day one. Rather than coordinating separately with an outside lab and hoping the results arrive before your transfer window, Lifeivfcenter’s treatment packages include clinical-grade genetic testing coordination, PGT support, and genetic counseling referral as part of a cohesive plan.
The Precision IVF® approach means your carrier screening results, embryo PGT findings, and ovarian reserve data are reviewed together, not in silos. If prior genetic test reports exist, bring them to your first consultation. The clinical team will assess whether confirmatory testing is needed and which PGT type fits your situation. For patients exploring fertility preservation packages alongside genetic planning, those conversations happen in the same appointment.
Schedule a consultation with Lifeivfcenter to review your genetic testing options and build a treatment plan that accounts for your complete reproductive picture.
Authoritative U.S. resources for further reading
- CDC Genetic Testing guidance: Clinical vs. DTC distinctions, CLIA regulation, and when to seek genetic counseling.
- MedlinePlus Genetics: Types of Genetic Tests: Plain-language explanations of molecular, chromosomal, and biochemical test categories.
- NCBI Understanding Genetics: Detailed background on carrier testing, inheritance patterns, and family planning implications.
- FORCE: Not All Genetic Tests Are Created Equal: Patient-advocacy perspective on clinical vs. DTC testing and lab accreditation.
- NIH Genetic Testing Registry (GTR): Searchable database of more than 64,000 clinical genetic tests, conditions, and accredited labs.
A genetic counselor remains the most reliable guide for interpreting any of these resources in the context of your personal and family history.
This article provides general educational information about genetic testing in fertility care. It is not a substitute for professional medical or genetic counseling advice. Consult a qualified provider for guidance specific to your situation.
Recommended
- The Role of Genetics in IVF: What Patients Need to Know
- Pre-IVF Pricing – Life IVF Center
- Your fertility evaluation checklist: Steps, tests, and benchmarks
- Blog – Life IVF Center
Ready to take the next step?
Life IVF Center specializes in individualized Precision IVF® care for complex cases—including diminished ovarian reserve, prior failed cycles, and advanced maternal age. Our in-house labs and dedicated physicians are ready to help.
Book a Free Consultation →